Cargando…

Higher Tumor Cellularity in Resected Pancreatic Ductal Adenocarcinoma Is a Negative Prognostic Indicator

BACKGROUND/AIMS: Desmoplasia is a prominent feature of pancreatic ductal adenocarcinoma (PDA). Stromal desmoplasia reflects the low cellularity that is characteristic of PDA, and it may play a role in PDA chemoresistance. In this retrospective study, we evaluated the relationship between tumor cellu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cho, In Kuk, Kim, Haeryoung, Lee, Jong-chan, Lee, Jongchan, Kim, Jaihwan, Ahn, Soomin, Park, Hyunjin, Hwang, Jin-Hyeok
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Editorial Office of Gut and Liver 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7366152/ https://www.ncbi.nlm.nih.gov/pubmed/31615191 http://dx.doi.org/10.5009/gnl19180

Ejemplares similares

Management of recurrent pancreatic cancer after surgical resection: a protocol for systematic review, evidence mapping and meta-analysis
por: Lee, Jong-chan, et al.
Publicado: (2018)

Combination immunohistochemistry for SMAD4 and Runt-related transcription factor 3 may identify a favorable prognostic subgroup of pancreatic ductal adenocarcinomas
por: Lee, Yangkyu, et al.
Publicado: (2017)

Postoperative muscle mass restoration as a prognostic factor in patients with resected pancreatic cancer
por: Lee, Jongchan, et al.
Publicado: (2020)

Four-Tier Pathologic Tumor Regression Grading System Predicts the Clinical Outcome in Patients Who Undergo Surgical Resection for Locally Advanced Pancreatic Cancer after Neoadjuvant Chemotherapy
por: Ahn, Soomin, et al.
Publicado: (2022)

Serum interleukin-6 is associated with pancreatic ductal adenocarcinoma progression pattern
por: Kim, Hyoung Woo, et al.
Publicado: (2017)

Initial Metastatic Site as a Prognostic Factor in Patients With Stage IV Pancreatic Ductal Adenocarcinoma
por: Kim, Hyoung Woo, et al.
Publicado: (2015)

High Expression of MicroRNA-196a Indicates Poor Prognosis in Resected Pancreatic Neuroendocrine Tumor
por: Lee, Yoon Suk, et al.
Publicado: (2015)

Multi-Phase, Contrast-Enhanced Computed Tomography-Based Radiomic Prognostic Marker of Non-Metastatic Pancreatic Ductal Adenocarcinoma
por: Shin, Dong Woo, et al.
Publicado: (2022)

Postoperative Carcinoembryonic Antigen as a Complementary Tumor Marker of Carbohydrate Antigen 19-9 in Pancreatic Ductal Adenocarcinoma
por: Kim, Jaihwan, et al.
Publicado: (2015)

Early versus delayed initiation of adjuvant treatment for pancreatic cancer
por: Kim, Hyoung Woo, et al.
Publicado: (2017)

Prognostic Value of Sarcopenia and Myosteatosis in Patients with Resectable Pancreatic Ductal Adenocarcinoma
por: Kim, Dong Wook, et al.
Publicado: (2022)

Presence of pancreatic intraepithelial neoplasia-3 in a background of chronic pancreatitis in pancreatic cancer patients
por: Hwang, In Kyeom, et al.
Publicado: (2015)

Circulating tumour cells as an indicator of early and systemic recurrence after surgical resection in pancreatic ductal adenocarcinoma
por: Park, Yejong, et al.
Publicado: (2021)

Clinical outcomes of FOLFIRINOX in locally advanced pancreatic cancer: A single center experience
por: Lee, Jongchan, et al.
Publicado: (2018)

Clinical Impact of Unexpected Para-Aortic Lymph Node Metastasis in Surgery for Resectable Pancreatic Cancer
por: Lee, Ho-Kyoung, et al.
Publicado: (2021)

Clinical impact of neoadjuvant treatment in resectable pancreatic cancer: a systematic review and meta-analysis protocol
por: Lee, Jong-chan, et al.
Publicado: (2016)

High PD-L1 expression is associated with therapeutic response to pembrolizumab in patients with advanced biliary tract cancer
por: Ahn, Soomin, et al.
Publicado: (2020)

Author Correction: High PD-L1 expression is associated with therapeutic response to pembrolizumab in patients with advanced biliary tract cancer
por: Ahn, Soomin, et al.
Publicado: (2020)

Comparison of Characteristics and Survival Rates of Resectable Pancreatic Ductal Adenocarcinoma according to Tumor Location
por: Sung, Min Kyu, et al.
Publicado: (2021)

Laparoscopic pancreaticoduodenectomy in pancreatic ductal adenocarcinoma
por: Choi, Munseok, et al.
Publicado: (2021)

Circulating tumor DNA as a prognostic indicator in resectable pancreatic ductal adenocarcinoma: A systematic review and meta-analysis
por: Lee, Jee-Soo, et al.
Publicado: (2019)

Neoadjuvant and Adjuvant Treatments for Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma: The Current Status of Pancreatic Ductal Adenocarcinoma Treatment in Japan
por: Ei, Shigenori, et al.
Publicado: (2023)

Deconvoluting cellular neighborhoods in pancreatic ductal adenocarcinoma
por: Lal, Jessica Castrillon
Publicado: (2022)

Clinical necessity of the immunohistochemical reassessment of para-aortic lymph nodes in resected pancreatic ductal adenocarcinoma
por: CHOI, SUNG HOON, et al.
Publicado: (2013)

Clinicopathological Features and Prognosis of Resected Pancreatic Ductal Adenocarcinoma Patients with Claudin-18 Overexpression
por: Park, Sejun, et al.
Publicado: (2023)

Neoadjuvant therapy versus upfront surgery in resectable pancreatic cancer according to intention-to-treat and per-protocol analysis: A systematic review and meta-analysis
por: Lee, Yoon Suk, et al.
Publicado: (2019)

Desmogleins as prognostic biomarkers in resected pancreatic ductal adenocarcinoma
por: Ormanns, Steffen, et al.
Publicado: (2015)

Pancreaticoduodenectomy for ductal adenocarcinoma of the pancreatic head with venous resection
por: Flis, Vojko, et al.
Publicado: (2016)

Contemporary management of borderline resectable pancreatic ductal adenocarcinoma
por: Lekka, Kyriaki, et al.
Publicado: (2019)

Contemporary Review of Borderline Resectable Pancreatic Ductal Adenocarcinoma
por: Bonds, Morgan, et al.
Publicado: (2019)

Untargeted metabolomics characterization of the resectable pancreatic ductal adenocarcinoma
por: Cao, Ying-Ying, et al.
Publicado: (2023)

Weak HIF-1alpha expression indicates poor prognosis in resectable pancreatic ductal adenocarcinoma
por: Leppänen, Joni, et al.
Publicado: (2018)

Plasminogen Activator Inhibitor 1 as a Poor Prognostic Indicator in Resectable Pancreatic Ductal Adenocarcinoma
por: Liu, Wen-Jing, et al.
Publicado: (2018)

Pancreaticoduodenectomy of Pancreatic Ductal Adenocarcinoma in the Elderly
por: Kang, Chang Moo, et al.
Publicado: (2007)

Potential prognostic biomarkers in pancreatic juice of resectable pancreatic ductal adenocarcinoma
por: Agrawal, Shefali
Publicado: (2017)

Pancreatic ductal adenocarcinoma: Prognostic indicators of advanced disease
por: Kruger, Deirdré, et al.
Publicado: (2022)

Clinical outcomes of pancreaticoduodenectomy for pancreatic ductal adenocarcinoma depending on preservation or resection of pylorus
por: Kim, Yeon Jin, et al.
Publicado: (2020)

Real-world outcomes of adjuvant gemcitabine versus gemcitabine plus capecitabine for resected pancreatic ductal adenocarcinoma
por: Kang, Sora, et al.
Publicado: (2022)

Alkaline Phosphatase-To-Albumin Ratio as a Prognostic Indicator in Pancreatic Ductal Adenocarcinoma after Curative Resection
por: Pu, Ning, et al.
Publicado: (2017)

Resection of pancreatic ductal adenocarcinoma with synchronous distant metastasis: is it worthwhile?
por: Buc, Emmanuel, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_1tu4rqfhn1st7smvj5psejj44a